ImmunoMet Oncogenesis: A New Concept to Understand the Molecular Drivers of Cancer
Open Access
- 27 February 2025
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (5) , 1620
Abstract
The appearance of cancer progresses through a multistep process that includes genetic, epigenetic, mutational, inflammatory and metabolic disturbances to signaling pathways within an organ. The combined influence of these changes will dictate the growth properties of the cells; the direction of further malignancy depends on the severity of these “disturbances”. The molecular mechanisms driving abnormal inflammation and metabolism are beginning to be identified and, in some cases, are quite prominent in pre-condition states of cancer and are significant drivers of the malignant phenotype. As such, utilizing signaling pathways linked to inflammation and metabolism as biomarkers of cancer is an emerging method and includes pathways beyond those well characterized to drive metabolism or inflammation. In this review, we will discuss several emerging elements influencing proliferation, inflammation and metabolism that may play a part as drivers of the cancer phenotype. These include AMPK and leptin (linked to metabolism), NOD2/RIPK2, TAK1 (linked to inflammation), lactate and pyruvate transporters (monocarboxylate transporter [MCT], linked to mitochondrial biogenesis and metabolism) and RASSF1A (linked to proliferation, cell death, cell cycle control, inflammation and epigenetics). We speculate that the aforementioned elements are important drivers of carcinogenesis that should be collectively referenced as being involved in “ImmunoMET Oncogenesis”, a new tripartite description of the role of elements in driving cancer. This term would suggest that for a better understanding of cancer, we need to understand how proliferation, inflammation and metabolic pathways are impacted and how they influence classical drivers of malignant transformation in order to drive ImmunoMET oncogenesis and the malignant state.Keywords
Funding Information
- Stollery Children’s Hospital/WCHRI Hair Massacure Donation Fund
This publication has 164 references indexed in Scilit:
- Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysisCancer Immunology, Immunotherapy, 2024
- Ripks and NeuroinflammationMolecular Neurobiology, 2024
- Is Metformin Associated with a Lower Prevalence of Polyps, Adenomas, and Colorectal Carcinoma in Patients with Diabetes Mellitus?Journal of Gastrointestinal Cancer, 2023
- SOD1, more than just an antioxidantArchives of Biochemistry and Biophysics, 2021
- TRAF Molecules in Inflammation and Inflammatory DiseasesCurrent Pharmacology Reports, 2017
- Gut microbiota changes in the extreme decades of human life: a focus on centenariansCellular and Molecular Life Sciences, 2017
- Biomarkers to predict prognosis and response to checkpoint inhibitorsInternational Journal of Clinical Oncology, 2017
- Early diagnosis of early-onset sarcoidosis: a case report with functional analysis and review of the literatureClinical Rheumatology, 2017
- The monocarboxylate transporter family—Role and regulationIUBMB Life, 2011
- The effects of NOS3 Glu298Asp variant on colorectal cancer risk and progression in Turkish populationMolecular Biology Reports, 2011